In addition to promoting an innate immune response within the TIME, TLR agonists, such as the TLR-2/3 agonist, L-pampo (LP) [85], and the TLR-7 agonist, Imiquimod [86], have been shown to induce tumor-cell ICD, as evidenced by enhanced ecto-CRT and the increased release of HMGB1 and ATP [85,86]. The gene discussed is HMGB1; the disease is neoplasm.